• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

digital therapeutics

Merck KGaA MilliporeSigma US
MedTech

Merck KGaA, Remepy team up on hybrid drugs for rare tumors

Merck KGaA is teaming up with Remepy to develop hybrid drugs that pair a pharmaceutical with a personalized, AI-driven digital component.
Natalie Missakian Apr 28, 2026 7:00am
A maze featuring a prescription bottle in the center

MindMaze seeks 'strategic alternatives,' eyes US expansion

Mar 3, 2026 9:25am
colorful brain art model

FDA clears Lumosity brain training games for adult ADHD

Dec 11, 2025 10:00am
schizophrenia mental health brain neurodegenerative

Boehringer, Click DTx hits phase 3 goal in schizophrenia

Oct 14, 2025 12:08pm
colorful brain art model

FDA clears prescription migraine app from Click Therapeutics

Apr 17, 2025 11:35am
Akili Endeavor

ADHD game developer Akili Interactive sold for $34M

May 30, 2024 11:23am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings